Drug development

Extraordinary General Meeting of Kinarus Holding approved all resolutions relating to the envisaged Business Combination with Curatis

Retrieved on: 
Wednesday, March 13, 2024

Basel, Switzerland, 1 March 2024: Kinarus Therapeutics Holding AG (SIX:KNRS) (“Kinarus Holding”, “KNRS” or the “Company”), a SIX Swiss Exchange listed therapeutic drug development company announced today that at the Extraordinary General Meeting of Kinarus Holding held on Friday, 1 March 2024, the shareholders of Kinarus Holding have approved with sweeping majorities all resolutions relating to the envisaged Business Combination with Curatis AG, a Basel-Landschaft incorporated medicine distribution and drug development company predominantly focused on orphan/ultra-orphan diseases and specialty care diseases (“Curatis”).

Key Points: 
  • Basel, Switzerland, 1 March 2024: Kinarus Therapeutics Holding AG (SIX:KNRS) (“Kinarus Holding”, “KNRS” or the “Company”), a SIX Swiss Exchange listed therapeutic drug development company announced today that at the Extraordinary General Meeting of Kinarus Holding held on Friday, 1 March 2024, the shareholders of Kinarus Holding have approved with sweeping majorities all resolutions relating to the envisaged Business Combination with Curatis AG, a Basel-Landschaft incorporated medicine distribution and drug development company predominantly focused on orphan/ultra-orphan diseases and specialty care diseases (“Curatis”).
  • Closing of the Transaction is expected to occur at the end of April 2024.
  • In addition to Kinarus Holding shareholder approval, completion of the proposed Business Combination is subject to satisfaction of certain other conditions.

Avance Clinical CEO Talks with SCRIP about US Biotech Sector "Green Shoots" and a New CRO Report

Retrieved on: 
Tuesday, February 27, 2024

(read the full article here)

Key Points: 
  • (read the full article here)
    Avance Clinical CEO, Yvonne Lungershausen was interviewed by SCRIP Intelligence about the current biotech financial and drug development climate in the US and signs of growth.
  • Investors are really being super cautious about where they're investing and relatively, there's not a high-risk appetite," Lungershausen said to SCRIP in the interview.
  • SCRIP Intelligence noted that Avance Clinical presented at JPM and Biotech Showcase a new analysis by market research leader, Frost & Sullivan on the biotech sector and the challenges they have finding the right fit or size CRO (See report here).
  • For more information about the benefits of running your next study with Avance Clinical contact us: [email protected]

Nusano Opens Radiochemistry Laboratory to Advance Isotope Commercialization and Customer Collaboration

Retrieved on: 
Monday, March 11, 2024

“Nusano is less than 12 months away from bringing critical, new radioisotope supplies to researchers, drugmakers and patients.

Key Points: 
  • “Nusano is less than 12 months away from bringing critical, new radioisotope supplies to researchers, drugmakers and patients.
  • We expect to begin producing non-carrier added lutetium-177 in Q1 2025, followed by actinium-225 in the second half of the year,” said Chris Lowe, CEO of Nusano.
  • Nusano is working to supply the fight against cancer by combining the company’s expertise in physics and radiochemistry to meet the medical isotope needs of today and enable the cancer radiotherapeutics of tomorrow.
  • Anna Goldberg, director of Radiochemistry and Production Operations for Nusano, added, “Nusano’s radiochemistry team is a world-class group of experts working at the forefront of their field.

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Retrieved on: 
Monday, March 11, 2024

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.

Key Points: 
  • SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.
  • “Deyaa’s leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need,” said Thane Wettig, Chief Executive Officer of FibroGen.
  • “We will benefit immensely from Deyaa’s broad and deep experience in oncology drug development, including his experiences in both pancreatic and prostate cancers.”
    “I am excited to join FibroGen and lead the clinical development organization at this important time for our company,” commented Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
  • Prior to joining FibroGen, he was the Chief Medical Officer of Triumvira Immunologics Inc. where he led the transition of two novel cell therapy programs into clinical development.

Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Friday, March 8, 2024

The Company's Interim Chief Executive Officer, Thomas Jensen, stated, “2023 was a year of remarkable achievements for Allarity Therapeutics as we made significant strides in advancing our DRP®-guided drug development.

Key Points: 
  • The Company's Interim Chief Executive Officer, Thomas Jensen, stated, “2023 was a year of remarkable achievements for Allarity Therapeutics as we made significant strides in advancing our DRP®-guided drug development.
  • Announced leadership changes and strategic advisory engagement:
    Appointment of co-founder Thomas H. Jensen as Interim Chief Executive Officer in December 2023.
  • With nearly two decades at Allarity Therapeutics, Jensen brings extensive experience and a deep understanding of the company’s DRP® to his new role.
  • Net Loss from Operations: Net Loss from Operations was $17.1 million for 2023, compared to $34 million for 2022.

PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease

Retrieved on: 
Thursday, March 7, 2024

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an insightful interview with Lipella Pharmaceuticals’ CEO, Dr. Jonathan Kaufman, discussing the company's recent regulatory accomplishments and how investors stand to benefit.

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an insightful interview with Lipella Pharmaceuticals’ CEO, Dr. Jonathan Kaufman, discussing the company's recent regulatory accomplishments and how investors stand to benefit.
  • Lipella Pharmaceuticals was recently granted Orphan Drug Designation by the FDA for LP-410, its drug candidate for oral Graft-versus-Host Disease (GvHD) and previously received Orphan Drug Designation for LP-10 in 2023.
  • Dr. Kaufman remarked, “Orphan drug development can often be more profitable, entail lower risk and result in faster time to approval than non-orphan therapeutics.
  • Our goal is to deliver safe and effective treatments as quickly as possible to the patients who need them most,” said Dr. Kaufman.

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Retrieved on: 
Thursday, March 7, 2024

SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).

Key Points: 
  • SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).
  • Dr. Lenz accelerates translational and clinical research and provides training and mentoring in the design and implementation of investigator-initiated trials.
  • In 1991, he completed his internship, residency, and fellowship training at the Eberhardt Karls Universität in Tübingen, Germany.
  • “His insight and clinical experience as a leading expert in colorectal cancer is of great importance as we develop our SAFEbody® ADG126 for patients worldwide.”
    For more information about members of the Adagene Scientific and Strategic Advisory Board, visit: https://www.adagene.com/about/key-advisors/

Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference

Retrieved on: 
Thursday, March 7, 2024

The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.

Key Points: 
  • The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.
  • The data presented further demonstrated how Telomir-1 increases telomere length and its potential to successfully affect age-related inflammatory conditions.
  • The collaboration is expected to help accelerate the development of Telomir-1, improve its safety profile, and significantly reduce the research and development costs of Telomir’s drug development program.
  • To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

Retrieved on: 
Wednesday, March 6, 2024

SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that it has appointed Steven Lo as President and Chief Executive Officer and a member of the Board of Directors, effective as of March 18, 2024. Mr. Lo is a highly experienced biopharma executive with over 25 years of experience in the healthcare, biotechnology, and pharmaceutical industries, including over 12 years of C-level experience in publicly traded biotech companies. Michael J. Finney, Ph.D. will step down as interim Chief Executive Officer and will continue to serve as Chair of the Board of Directors.

Key Points: 
  • Michael J. Finney, Ph.D. will step down as interim Chief Executive Officer and will continue to serve as Chair of the Board of Directors.
  • Lo.
  • Lo was most recently with Valitor, Inc., a private biotech company, serving as its Chief Executive Officer and a member of the board of directors since 2022.
  • Lo was the President, Chief Executive Officer, and member of the board of directors of Zosano Pharma Corporation, a clinical-stage biopharmaceutical company.

Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

Retrieved on: 
Wednesday, March 6, 2024

WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board.

Key Points: 
  • WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board.
  • Mr. Dable succeeds Mark Iwicki, who will continue to serve on the Board.
  • “We are pleased to have Habib take on the role of Chair of the Board,” said Tim Noyes, Chief Executive Officer of Aerovate Therapeutics.
  • I would also like to thank Mark for his significant contributions and commitment to Aerovate, and I look forward to continuing to work together.”
    “I am honored to assume the role of Board Chair for Aerovate during this exciting time for the company,” said Mr. Dable.